OUR PORTFOLIO

Our portfolio includes grants and mission-related investments supporting Alzheimer’s drugs in development, biomarkers, prevention programs, and other projects designed to build the capacity of the field. You can explore the programs we have supported using the filter and “Search Database” options in the sidebar.

All Filters

Clear
Clear
Clear
Clear
Clear
Clear
Clear
Investigator: Michela Gallagher

2 Projects | 1 Researchers | $394,500 Invested

2018

AgeneBio Inc

Michela Gallagher, PhD

2018 Annual Goodes Prize for Excellence in Alzheimer’s Drug Discovery: Imaging Sub-study for the HOPE4MCI Phase 3 Trial

  • Funding Amount: $150,000
  • Organization Type: Biotechnology/For Profit
  • Program: Clinical
  • Target: Synaptic Activity and Neurotransmitters
  • Status: Closed

2010

AgeneBio Inc

Michela Gallagher, PhD

Selective GABA a5 ligands for cognitive enhancement in patients with Mild Cognitive Impairment

  • Funding Amount: $244,500
  • Organization Type: Biotechnology/For Profit
  • Program: Drug Discovery
  • Status: Closed